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Introduction: We report lung stereotactic-body radiotherapy (SBRT) 
outcomes for a large pooled cohort treated using daily online cone-
beam computed tomography.
Methods: Five hundred and five stage I–IIB (T1-3N0M0) non–small-
cell lung cancer (NSCLC) cases underwent SBRT using cone-beam 
computed tomography image guidance at five international institu-
tions from 1998 to 2010. Median age was 74 years (range, 42–92) 
whereas median forced expiratory volume in 1 second/diffusing 
lung capacity for carbon monoxide were 1.4 liter (65%) and 10.8 ml/
min/mmHg (53%). Of the 505 cases, 64% were biopsy proven and 
87% medically inoperable. Staging was: IA 63%, IB 33%, IIA 2%, 
and recurrent 1%. Median max tumor dimension was 2.6 cm (range, 
0.9–8.5). Median heterogeneously calculated volumetric prescription 
dose (PD) was 54 Gy (range, 20–64 Gy) in three fractions (range, 
1–15) over 8 days (range, 1–27). Median biologically equivalent PD 
biological equivalent doses (BED
10
) was 132 Gy (range, 60–180).
Results: With a median follow-up of 1.6 years (range, 0.1–7.3), the 
2-year Kaplan–Meier local control (LC), regional control, and dis-
tant metastasis (DM) rates were 94%, 89%, and 20%, respectively, 
whereas cause-specific and overall survival were 87% and 60% (78% 
operable, 58% inoperable, p = 0.01), respectively. Stage, gross-tumor 
volume size (≥ 2.7 cm) and PD(BED
10
) predicted local relapse (LR) 
and DM. LR was 15% for BED
10
 less than 105 Gy versus 4% for 
BED
10
 of 105 Gy or more (p < 0.001); DM was 31% versus 18% 
for BED
10
 less than 105 versus 105 Gy or more (p = 0.01). On mul-
tivariate analysis, PD(BED
10
) and elapsed days during radiotherapy 
predicted LR; gross-tumor volume size predicted DM. Grade 2 or 
higher pneumonitis, rib fracture, myositis, and dermatitis were 7%, 
3%, 1%, and 2%, respectively.
Conclusions: In the largest early-stage NSCLC SBRT data set to 
date, a high rate of local control was achieved, which was correlated 
with a PD(BED
10
) of 105 Gy or more. Failures were primarily distant, 
severe toxicities were rare, and overall survival was encouraging in 
operable patients.
Key Words: Non–small cell lung cancer, Stereotactic body radio-
therapy, Image-guided radiotherapy.
(J Thorac Oncol. 2012;7: 1382–1393)
Surgical resection including anatomic pulmonary resection or lobectomy with mediastinal lymph node dissection or 
systematic sampling is the preferred treatment for patients 
with stage I (T1-2 N0 M0) and selected stage IIB (T3 N0 
M0) non–small-cell lung cancer (NSCLC). In patients with 
poor pulmonary reserve or other major medical comorbidities 
that preclude lobectomy, sublobar resections including 
segmentectomy or wedge resection are acceptable lower-risk 
surgical options, particularly for patients with small peripheral 
tumors.1 For patients deemed medically inoperable after 
multidisciplinary evaluation, nonsurgical treatment options 
include fractionated radiotherapy or three-dimensional (3D) 
conformal radiotherapy (3DCRT), stereotactic radiotherapy 
(also called stereotactic-body radiotherapy [SBRT] or 
stereotactic ablative radiotherapy), or less commonly, 
radiofrequency ablation or cryotherapy. Only SBRT or 
stereotactic ablative radiotherapy (RT) is currently described 
as the nonsurgical treatment option of choice and is advocated 
in the National Comprehensive Cancer Network guidelines 
(version 2.2012) for the management of early-stage medically 
inoperable NSCLC. This is because of the high local control 
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(LC) and overall survival (OS) rates reported using SBRT 
in prospective studies, comparable to surgery and higher 
than conventionally fractionated 3DCRT in nonrandomized 
studies.2–5 Nonrandomized comparisons of limited surgical 
resection to SBRT have shown similar outcomes in terms 
of LC and cancer-specific survival.6,7 In addition, SBRT 
substantially lowers the required number of treatment visits 
(6–8 weeks of RT versus generally 1–5 or so visits for RT 
fractions) for an elderly and sometimes frail population, and 
cost-effectiveness studies have found SBRT to be more cost-
effective than either 3DCRT or radiofrequency ablation; this 
is largely related to successful treatment outcomes.8,9
One of the initial concerns with delivering lung SBRT 
was finding an appropriate method for accurate tumor target-
ing, given the large doses of RT delivered per fraction, the 
potential for tumor miss or overdosing normal tissues, and 
the high biological dose, similar to the concept of stereotac-
tic radiosurgery in the brain (commonly using a stereotactic 
halo/head frame for targeting). These factors led to the use 
of a stereotactic body frame with coordinates, and many of 
the initial SBRT experiences used the combination of body-
frame coordinates with standard mega-voltage portal imag-
ing on the linear accelerator for verification, but without any 
method for true 3D (or volumetric) imaging on the treatment 
machine. The potential set-up errors using only a body frame 
for positioning, however, have been shown to be large.10–12 The 
advent of online or on-board (directly on the linear accelerator 
treatment machine) Computed tomography (CT) imaging in 
the form of cone-beam computed tomography (CBCT), how-
ever, made 3D verification of the tumor (or target) position 
possible on a daily basis, immediately before x-ray beam-on, 
better termed online image guidance or image-guided radio-
therapy (IGRT) (a few examples of such machines are: Elekta 
Synergy, Infinity, Axesse; Varian Trilogy). Other systems like 
CyberKnife (Accuray Inc., Sunnyvale, CA) also make 2-D 
verification of the target somewhat more accurate but require 
placement of tumor fiducials. Although SBRT series report 
quite favorable outcomes (LC rates in the 80%–95% range), 
some studies have identified a larger dose response 13 than oth-
ers have, 4–16 and some of these dose-response differences 
might ultimately relate to the lack of routine IGRT use.
In general, the SBRT literature comes primarily from 
one of two sources: either1 small phase I- and II-studies, typi-
cally single-institution or2 larger data sets not routinely requir-
ing 4D treatment planning methods (accounting for respiratory 
tumor-induced motion), IGRT, or volumetric (3D, noniso-
centric) prescriptions with a minimum dose delivered to the 
edge of the target volume. The current analysis focuses on a 
unique, large, multi-institutional, pooled cohort of early-stage 
NSCLC patients treated with SBRT. The data set is unique 
in that nearly all patients received daily online CBCT for 3D 
IGRT and analyses were performed of heterogeneity-corrected 
3D target doses, substantially reducing delivery uncertainties 
on outcome. Patients were treated at one of five institutions 
internationally recognized for advanced RT expertise, particu-
larly IGRT, with similar philosophies regarding target-volume 
definitions and 4D planning. Although the routine availability 
and application of online IGRT in this study does not directly 
verify the RT dose delivered to the target, it certainly makes us 
more confident that the dose delivered to the target should have 
been extremely similar to the RT dose prescribed.
MATERIALS AND METHODS
A total of 505 lung tumors in 483 patients were treated 
with SBRT between 1998 and 2010 at five institutions 
internationally (William Beaumont Hospital, Royal Oak, 
Michigan; University of Wuerzburg, Wuerzburg, Germany; 
Netherlands Cancer Institute, Amsterdam, The Netherlands; 
Princess Margaret Hospital, University of Toronto, Toronto, 
Ontario, Canada; and Thomas Jefferson University Hospital, 
Philadelphia, PA). All patients were diagnosed with American 
Joint Commission on Cancer 6th edition clinical stage IA–
IIB (T1–T3 N0 M0; peripheral T3 including chest-wall inva-
sion only) or locally recurrent (after prior wedge resection) 
NSCLC. One center excluded all patients with tumors located 
within 2 cm of the proximal bronchial tree; two prescribed dose 
according to location; one specified dose constraints for the 
proximal bronchial tree and trachea for eligibility.10 All patients, 
with the exception of those treated before 2005 (n = 23), who 
underwent offline CT verification just before beam-on, received 
SBRT on a linear accelerator equipped with CBCT using online 
IGRT (Elekta, Stockholm, Sweden) with each treatment frac-
tion. Each center followed an independent Institutional Review 
Board-approved treatment protocol for SBRT.
Pretreatment Evaluation
All patients underwent staging including a history and 
physical, CT scan of the chest and upper abdomen (including 
the liver and bilateral adrenals), and serum chemistries. 
Staging 18-fluorodeoxyglucose positron emission tomography 
(18FDG-PET) scans were obtained for 446 cases (88%). 
Baseline pulmonary function test (PFT) results were available 
for 88%. At one center, mediastinoscopy was performed at the 
physician’s discretion in 25 patients (5%). A total of 325 cases 
(64%) had biopsy-proven NSCLC. Tumor biopsies were more 
commonly performed at U.S. centers than those outside the 
United States (William Beaumont Hospital 87%, Netherlands 
Cancer Institute 41%, Thomas Jefferson University 95%, 
Princess Margaret Hospital 72%, and University of Wuerzburg 
70%). Two centers routinely performed a bone scan, and three 
centers performed either a brain magnetic resonance imaging or 
head CT scan as part of the routine staging work-up. Fifty-six 
patients (11%) were considered operable, 392 were medically 
inoperable (78%), and the status of operability was unknown 
for 57 patients (11%). Operability was independently defined by 
each institution, but patients underwent routine multidisciplinary 
evaluation including thoracic surgical evaluation, with operability 
determined at physician discretion based on pulmonary function 
and medical comorbidities. Baseline PFTs are shown with 
patient characteristics in Table 1. The median time from staging 
CT-PET to SBRT start was 5.7 weeks.
Treatment
For SBRT planning, a CT simulation with 3D planning 
was performed for all cases. Immobilization methods 
varied among centers and included a Stereotactic Body 
Frame (Elekta Oncology, Norcross, GA), BodyFix (Elekta 
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Oncology), alpha-cradle (KGF Enterprises, Chesterfield, 
MI), chest board plus arm support, or supine position without 
custom immobilization. After 2006, all centers required a 
respiratory-correlated 4D CT scan for treatment planning. 
All centers outlined the gross-tumor volume (GTV) using 
CT lung windows. At two centers, an internal target volume 
(ITV) was defined as the union of the GTV on all 10 phases 
of the 4D CT scan. Two centers defined the ITV as the union 
of the GTV on the two extreme phases of the respiratory 
cycle (normal maximum inspiration and normal maximum 
expiration). One center used the midventilation CT phase 
(time-weighted mean tumor position) to define a GTV
average
 
and applied a patient-specific margin that was variable in 
three dimensions based on the 4D CT.17 Two centers expanded 
the ITV by 0.4 to 0.7 cm to define a clinical target volume 
(CTV), whereas three centers used no expansion for the 
CTV. The CTV was expanded in a patient-specific manner by 
a minimum of 0.5 cm in all directions to form the planning 
target volume (PTV) at all centers. Treatment was delivered 
via 6 to 18 MV photons (typically 6 MV) with five to 12 
coplanar or noncoplanar beams using segments that were 
either manually (two centers) or inversely (three centers) 
TABLE 1.  Patient, Staging, or Treatment Characteristics and Prescription-Dose Data
Characteristic Median Range Percentage (%)
Age (yrs) 74 42–94
ECOG performance status 1 0–3
Sex
 Male 52
 Female 48
Baseline pulmonary function
 FEV1 1.4 liter 0.4–4.4 liter
 FEV1 %predicted 64% 21%–186%
 DLCO 10.8 ml/min/mmHg 3.4–27.6
 DLCO %predicted 53% 10%–103%
Biopsy proven 64
PET-staged 88
Staging mediastinoscopy 5
Adjuvant chemotherapy 3
Clinical stage
 IA (T1 N0) 63
 IB (T2 N0) 33
 IIA (T3 N0) 2
 Local recurrence 1
GTV maximum dimension 2.6 cm 0.9–8.5 cm
<2.7 cm 53
≥2.7 cm 47
Histology
 Adenocarcinoma 47
 Squamous cell carcinoma 32
 Large cell/NOS/mixed 22
Grade
 1 12
 2 48
 3 40
Median GTV and PTV Prescription Doses; Lung Dose–Volume Histogram Parameters
Median (Range) Absolute Dose (Gy) BED
10
(Gy)
2-Gy Fraction 
Equivalent (Gy) Ratio
GTV mean dose 66.1(30.0–90.0) 188.4(77.7–360.1) 157.0(64.8–300.0)
PTV mean dose 60.7(25.1–79.4) 164.7(75.7–289.9) 137.2(63.1–241.5)
PTV Dmax/Dmin 1.47(1.03–8.07)
Bilateral lungs–GTV V
20
5.6%(0.1%–21.9%)
Bilateral lungs–GTV mean dose 6.0 Gy(0.9–17.8 Gy)
ECOG, Eastern Cooperative Oncology Group; FEV1, forced expiratory volume in 1 second; DLCO, diffusing lung capacity for carbon monoxide; PET, positron emission tomog-
raphy; NOS, not otherwise specified; BED
10
, biological equivalent doses; GTV, gross-tumor volume; PTV, planning target volume; V20, volume of lung receiving 20 Gy.
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optimized using dynamic machine parameter optimization 
(Philips Medical Systems, Milipitas, CA) for a single segment 
per beam without intensity modulation. Occasionally, 
multiple segments were used (intensity modulated radiation 
therapy), but only if dose-limiting constraints could not be 
met. The dose was calculated with heterogeneity correction 
using an adaptive convolution superposition (collapsed cone) 
algorithm (Pinnacle; Philips Medical Systems ). Few patients 
were treated using a homogeneously calculated dose plan; all 
were recalculated using heterogeneity correction for analysis. 
All centers used volumetric prescriptions to the PTV edge 
with 10% to 40% target heterogeneity (i.e., the dose was 
prescribed such that the periphery of the target received the 
prescription dose (PD) as a minimum and was 10% to 40% 
hotter in the center, rather than an isocentric prescription that 
creates a homogeneous plan with the center and the edge 
receiving the same dose). There was substantial variation 
among centers in dose prescription as outlined in Figure 1 and 
Appendix A. 3-D dose–volume data including the GTV and 
PTV were available for 475 cases (94%). Normal tissue dose–
volume constraints were either institution-dependent and 
previously published or the same as dose volume constraints 
used in ongoing or completed Radiation Therapy Oncology 
Group (RTOG) lung SBRT protocols (see additional data 
provided in Appendix B per institution and RTOG protocol 
guidelines18). All centers performed daily online correction 
using CBCT based on the tumor location using grayscale 
soft-tissue–based image registration via XVI (Elekta). Four 
centers performed three CBCT per fraction: precorrection, 
postcorrection, post-treatment; one center also performed a 
midfraction CBCT. At one center, 17 patients (3%) received 
adjuvant chemotherapy at physician discretion, starting at 
least 6 weeks after completion of SBRT.
Follow-Up
All patients underwent routine follow-up including a 
CT scan of the chest every 3 to 6 months for the first 2 years. 
Follow-up 18FDG-PET scans were performed variably depend-
ing on the institution but were used in cases of suspected CT 
progression. Local recurrences were defined using either the 
combination of CT progression and 18FDG-PET avidity at the 
site of the original tumor location or documented by biopsy 
whenever possible. Given the substantial lung parenchy-
mal changes that can occur after SBRT, standard Response 
Evaluation Criteria In Solid Tumors criteria could not nec-
essarily be followed for response or progression. Regional 
recurrences were defined as failure within the regional lymph 
node stations. Locoregional recurrence included patients 
with local, regional, or both local and regional recurrences. 
Distant failures were failures beyond either the local region 
or regional nodes. Regional and distant failures were docu-
mented by either biopsy or the combination of CT plus PET 
progression. Toxicities were scored based on National Cancer 
Institute Common Toxicity Criteria version 3. The mean 
potential follow-up for all patients was 2.6 years (median 2.3 
years). The mean follow-up was 1.6 years (median 1.3 years).
Statistics
A single center (William Beaumont Hospital) housed 
and analyzed all data using an experienced medical statisti-
cian after it was collected, anonymized, and verified by the 
individual institutions that treated and followed the patients 
either prospectively or retrospectively. The Student’s unpaired 
t test and Pearson χ2/Fisher’s exact test were used to compare 
continuous and categorical variables among groups, respec-
tively, for similarities among patient subgroups with respect 
to patient, treatment, or tumor-related factors. Analyses of 
local relapse (LR), regional recurrence (RR), distant metas-
tasis (DM), and survival were calculated and compared using 
the Kaplan–Meier method. Analyses of LR were calculated 
per individual tumor whereas analyses of regional or distant 
recurrence and survival were calculated per patient. For analy-
ses of outcomes according to dose, biological equivalent doses 
(BED
10
) were calculated using the following formula: BED = 
total dose (nd) × relative effectiveness, where relative effec-
tiveness = 1 + d/[α/β]. Here n is the number of fractions and 
d is the local dose per fraction and α/β is the ratio of intrin-
sic radiosensitivity to (mis)repair capacity for the appropriate 
tissue, in this case, taken as 10 Gy for rapidly proliferating 
carcinoma (lung cancer).19 Receiver operating characteristics 
(ROC) curves were used to test different prognostic factors 
in predicting outcome, with their performances measured 
based on the area under the ROC curve. Multivariate analy-
ses used Cox regression. A p value of 0.05 or lesser or 95% 
CI not encompassing 1 was considered statistically signifi-
cant. Statistical analyses were performed with SPSS Statistics 
Version 17.0 (SPSS Inc., Chicago, IL), and all statistical tests 
were two-sided.
FIGURE 1.  Distribution of prescription-dose BED10. BED10, 
biological equivalent doses; NKI, Netherlands Cancer 
Institute; TJU, Thomas Jefferson University Hospital; PMH, 
Princess Margaret Hospital.
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RESULTS
Five hundred and five lung tumors in 483 patients were 
treated with SBRT and followed for a mean of 1.6 years with 
a range of 0.1 to 7.3 years (median, 1.3 years). Surviving 
patients were followed for a mean of 1.7 years and median 
of 1.5 years. Detailed patient and tumor characteristics are 
shown in Table 1. The median age was 74 years with a range 
of 45 to 92 years; 52% of the cases were male. Clinical stage 
was IA in 63%, IB in 33%, IIA in 2%, or a recurrent tumor in 
1%. Fifty-six patients (11%) were considered operable, 392 
were medically inoperable (78%), and the status of operability 
was unknown for 57 patients (11%). Some form of PFT 
data were available in 88% of patients; 88% had FEV1 data, 
and 66% had diffusing lung capacity for carbon monoxide 
(DLCO) data. Median FEV1 was 1.4 liters, 64% of predicted; 
median DLCO was 10.8 ml/min/mmHg, 53% of predicted. 
Median maximum tumor dimension was 2.6 cm (contoured 
GTV) (range, 0.9–8.5 cm). Thirty-seven patients (8%) had 
a synchronous primary tumor; 20 synchronous tumors 
received SBRT; 61 patients (13%) had prior or subsequent 
metachronous primary lung tumors.
Prescription dose varied according to institutional pref-
erence/protocol. Appendix A outlines the dose schedules 
according to institution and the equivalent dose if one were 
using standard 2-Gy fractions. Median volumetric PD was 
54 Gy (range, 18–64 Gy) and median dose per fraction was 
12.5 Gy (range, 4.2–26 Gy). Median number of fractions was 
3 (range, 1–15), delivered over a median of 8 elapsed days 
(range, 1–27). Median BED
10
 (BED using an alpha-beta for 
tumor of 10) was 132 Gy (range, 50.4–180 Gy), correspond-
ing to 110 Gy in 2-Gy fraction equivalents. Heterogeneity-
corrected dose data for GTV and PTV minimum, maximum, 
and mean values were available in 94% of the cases (Table 1); 
planning target volume dose to 1% of the PTV (PTVD
1
) and 
to 99% of the PTV (D
99
). Median values for lung dose–vol-
ume data are also shown in Table 1. Table 2 and Figure 2 
show Kaplan–Meier recurrence and survival outcomes. There 
were 26 local recurrences, 12 of which were biopsy proven. 
The 2-year Kaplan–Meier rate of LR was 6%, RR 11%, and 
DM 20%. Two-year OS and cause-specific survival (CSS) for 
all patients were 60% and 89%, respectively. No institution 
routinely offered SBRT to operable patients; however, 11% 
of patients were medically operable but refused or declined 
surgery. The 2-year OS rate in operable patients was 78% 
compared with a 2-year OS of 58% in medically inoperable 
patients (p = 0.006).
Table 3 shows 2-year outcomes (LR, RR, DM) by patient 
subgroup (univariate analyses). The most significant factors 
for LR were prescription BED
10
 and GTV maximum dimen-
sion (continuous and categorical). GTV size was associated 
with LR on univariate analysis as both a continuous and cat-
egorical variable (p = 0.02) with 2-year LR of 3% for less than 
2.7 cm versus 9% for 2.7 cm or more (p = 0.03). Clinical stage 
was significant for LR when comparing all stages (p < 0.001), 
however, not upon comparison of only T1 versus T2 tumors 
(p = 0.23). Prescription dose BED
10
 105 Gy (most closely 
approximates 12 Gy × 4 fractions) corresponded to a volumet-
ric target dose of 125 Gy for PTV
mean
 and 147 Gy for GTV
mean
. 
On ROC analysis, prescription BED
10
 demonstrated the high-
est area under the curve (at 0.693 (p < 0.001). ROC analysis 
revealed an optimal cut point of 105 Gy for prescription BED
10
 
with a sensitivity of 81% and specificity of 50%. Prescription 
BED
10
 of 105 Gy or more versus BED
10
 less than 105 Gy was 
significantly associated with lower local recurrence, 4% ver-
sus 15%, p < 0.001 (Fig. 3). This dose–response relationship 
held true in dose quartiles up to BED 152 Gy, with the risk of 
recurrence being 15%, 6%, 4%, and 0%, p = 0.00114 (see Table 4). 
All BED
10
 GTV and PTV endpoints were significantly associ-
ated with LR as continuous variables on univariate analysis 
(p < 0.05). Prescription dose and PTV
mean
 dose, however, 
seemed to have the highest correlation with LR. The area 
under the ROC curve was 0.65 for PTV
mean
 dose, with an opti-
mal cut point of 125 Gy for local control and a sensitivity and 
specificity of 84% and 57%, respectively, for predicting LR. 
Two-year LR was 4% for PTV
mean
 more than 125 Gy versus 
17% for PTV
mean
 less than 125 Gy (p < 0.01). Longer treat-
ment duration (≥11 elapsed days) demonstrated a 2-year LR of 
14% versus 4% for 10 days or lesser (p < 0.01). Synchronous 
primary tumors had higher rates of regional recurrence and 
DM, but were not more likely to recur locally. A more detailed 
TABLE 2.  Two-Year Kaplan–Meier Recurrence and Survival Outcomesa
All Cases
Event
No. of 
Events
2-Year 
Rateb(%)
3-Year 
Rateb(%)
Biopsy-Proven Cases Only
(n = 325 Tumors; 320 Patients) (%) 2-Year (%) p
2-Yr Rate 3-Yr Rate
Local recurrence 26 6 9 7 10
Regional recurrence 37 11 14 11 12
Distant metastasis 65 20 21 21 23
Overall survival 181 60 48 61 50
Operable 78c 0.006
Medically Inoperable 58
Cause-specific Survival 52 87% 77% 86% 78%
aLocal recurrence analyzed per tumor; all other endpoints analyzed per patient; n = 505 tumors, n = 483 patients.
bNo statistically significant differences in any endpoint for biopsied nonbiopsied tumors. 
cTwo-yr rates.
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analysis of these factors predicting local recurrence will be 
presented in a separate report.
On univariate analysis, DM was predicted by lack of PET 
staging (27% versus 19%, p = 0.04), clinical stage (15% T1, 27% 
T2, 42% T3, p = 0.005), GTV maximum dimension (p = 0.004), 
synchronous primary tumor (38% versus 18%, p = 0.05) and 
prescription BED
10
 (p = 0.01). LR or RR significantly predicted 
for DM, with either recurrence associated with an approximate 
doubling of the DM rate (p = 0.005, p = 0.001).
Cox multivariate analysis (Table 5) demonstrated pre-
scription BED
10
 to be the strongest predictor of LR (p = 0.01), 
followed by elapsed days during SBRT (p = 0.05). Time from 
staging PET to SBRT borderline predicted RR; squamous his-
tology borderline predicted DM. GTV maximum dimension 
TABLE 3. Univariate Analysis: 2-Year Clinical Outcomes According to Subgroup
Characteristic
Local 
Recurrence (%) p
Regional 
Recurrence (%) p
Distant 
Metastasis (%) p
Age (yrs)a
 < 70 8 0.04 0.86 25 0.08
 70–79 8 18
 ≥ 80 1 16
Sex 0.19 0.54 0.64
Biopsy proven 0.60 0.77 0.29
PET staging
 No 10 0.89 3 0.06 27 0.04
 Yes 6 12 19
Mediastinoscopy 0.38 0.52 0.15
Grade 0.60 0.21 0.15
Chemotherapy
 No 6 0.84 11 0.21 21 0.09
 Yes 13 0 0
Clinical stage
 IA T1N0 4 <0.001 10 0.20 15 0.005
 IB T2N0 8 IA vs. IB; p = 0.23 10 27 IA vs. IB; p = 0.01
 IIA T3N0 33 0 42
 Local recurrence 20 47 47
Synchronous primary
 No 7 0.94 9 0.03 18 0.05
 Yes 3 25 38
GTV max dimension
 < 2.7 cm 3 0.03 9 0.21 13 0.004
 ≥ 2.7 cm 9 12 27
Histology
 Adenocarcinoma 8 0.61 7 0.08 17 0.09
 Squamous cell 10 12 29
 Large cell/NOS/mixed 3 17 20
Elapsed days during RTb 0.05 0.77 0.74
Local recurrence
 No — — 10 0.37 18 0.005
 Yes 14 38
Regional recurrence
 No 6 0.32 — — 18 0.001
 Yes 6 — — 42
Prescription dose
 BED
10
 < 105 Gy 15 <0.001 14 0.63 31 0.01
 BED
10
 ≥ 105 Gy 4 10 18
Bold text indicates statistical significance. Italics indicate a statistical trend.
aAlthough age was significantly associated with local recurrence on univariate analysis only, there was a statistically significant difference in follow-up time for older vs. younger 
patients, p = 0.01 (linear regression).
bt test p value for comparison of the means. Mean value for no local recurrence; local recurrence was 8.9 days 10.7 days. 
NOS, not otherwise specified; RT, radiotherapy; BED
10
, biological equivalent dose calculated using alpha/beta = 10 for tumor.
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FIGURE 2.  Kaplan–Meier survival curves after lung stereotactic-body radiotherapy. (A) Local control, (B) regional control, (C) 
freedom from distant metastasis, (D) overall survival, and  (E) cause-specific survival. 
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was the only significant predictor of DM and CSS on multi-
variate analysis. Baseline DLCO (p = 0.005), sex (p = 0.02, 
hazard ratio of men 2.175), and time from staging PET to 
SBRT (p = 0.02) predicted OS. Prescription-dose BED
10
 sig-
nificantly predicted OS (65% versus 43% for high versus low 
dose, p = 0.001) and CSS (93% versus 73% for high versus 
low dose, p < 0.001) on univariate analysis only.
SBRT was well tolerated. Grade 2 or higher pneumo-
nitis developed in 7% of patients, with 2% having grade 3 or 
higher pneumonitis (median time to pneumonitis 0.4 years). 
A single case of fatal (grade 5) pneumonitis (0.2%) developed 
in a patient on continuous oxygen pre-SBRT with an FEV1 of 
0.8 liter; the patient died of respiratory failure within 8 weeks of 
SBRT. Multiple clinical and dose volume histogram variables 
(age, sex, synchronous primary tumor, baseline pulmonary func-
tion, tumor size, PD, lungs–GTV V
20
, lungs–GTV mean dose, 
and lungs–GTV BED
3
) were analyzed for association with pneu-
monitis, with synchronous primary the only significant predictor 
(p < 0.001). Nineteen percent of those treated for synchronous 
primary tumors developed grade 2 or higher pneumonitis.
Post-SBRT rib fractures occurred in 8% (3% grade ≥ 2; 
1% grade ≥ 3; median time 0.9 years) and were statistically 
more common with higher BED. The mean prescription 
BED
10
 for fracture versus none was 124 Gy versus 141 Gy 
(p < 0.001). Prescription BED
10
 had an area under the curve 
of 0.659 (p = 0.001) for rib fracture, with an optimal ROC 
cut point of 132 Gy for a fracture rate of 11% versus 5%, 
p = 0.007. Acute myositis rate developed in 7% (1% grade 
≥ 2, 0.2% grade ≥ 3); chronic myositis 5% (1% grade ≥ 2, 
0.2% grade ≥ 3). Two percent of patients had grade 2 or higher 
dermatitis.
DISCUSSION
In this study, we report not only on the largest data set 
of patients treated with lung SBRT for early-stage NSCLC 
to date, but also on a unique data set in which patients were 
treated with 3D IGRT via online CBCT in 95.5% of cases 
for target accuracy. Although treated across five international 
institutions with variation in staging and a broad range of 
PDs, treatment planning and delivery methods were similar, 
and all analyses of dose–volume relationships and clinical 
outcome were based on heterogeneity-corrected dose that 
more accurately depicts the dose delivered to both tumor 
and normal tissues. SBRT was well tolerated with only 7% 
patients having grade 2 or higher pneumonitis (2% ≥ grade 3). 
Seven percent to eight percent of the patients had post-SBRT 
chest-wall symptoms (rib fractures or myositis), and less 
than 1% developed grade 3 dermatitis. LC rates reported in 
smaller series2,14,20–26 were substantiated in this large data set 
(94% 2-year LC; 91% 3-year LC) and a significant dose–
response relationship was observed for prescription BED
10
 
of 105 Gy or more (2-year LC 96%) or of less than 105 Gy 
(2-year LC 85%). Tumor size and elapsed days during SBRT 
were also important. Three-dimensional target doses were also 
associated with LC, but the details are beyond the scope of this 
study and the subject of another report. Regional recurrence 
was 11%, but not predicted by the use of staging PET or 
mediastinoscopy. DM (2-year 20%) was the predominant site 
of failure and predicted by GTV size (97% of the patients 
had no systemic therapy). Although only 64% of the tumors 
were biopsied because of severe comorbidities, no differences 
in any clinical endpoint were identified for biopsied versus 
nonbiopsied tumors. A 3-year OS rate of 48% (2-year 60%) in 
this predominantly inoperable population is not unexpected, 
still higher than historical fractionated RT rates.27–32 The 
survival rate in operable patients is also encouraging.
The current data set represents the largest pooled cohort 
to date of early-stage NSCLC patients receiving SBRT and 
is unique in its consistent application of online 3D IGRT and 
analysis of 3D and heterogeneity-corrected dose. Although 
other studies that report high LC, and assess dose–response 
relationships do exist, none are of comparable size or con-
sistency. The most commonly cited analysis is the pooled 
Japanese report 15 identifying a similar BED level for LC (100 
Gy; 5-year LC 84%), but with doses prescribed to isocenter, no 
analysis of volumetric dose, and a large variety of IGRT meth-
ods.15 Some have suggested as well that results derived from 
a strictly Asian population may not be immediately applicable 
to others (potential tumor biology differences cited). Although 
Wulf et al.16 also identified BED 100 Gy (volumetric dose) to 
TABLE 4. Two-Year Local Recurrence According to 
Prescription BED10
Prescription Dose
Percentage of 
Patients (%)
Local 
Recurrence (%) p
BED
10
 < 105 Gy 20 15 <0.001
BED
10
 ≥ 105 Gy 80 4
BED
10
 < 105 Gy 20 15 0.001
BED
10
 106–132 Gy 26 6
BED
10
 133–152 Gy 49 4
BED
10
 ≥ 152 Gy 4 0
BED
10
, biological equivalent doses.
FIGURE 3.  Local recurrence according to prescription  
biological equivalent doses.
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be a significant cutoff for LC, they used mobile CT for verifi-
cation and included only 36 primary NSCLC cases. Although 
Guckenberger et al.33 used 3D dose data with heterogeneity 
correction and reported higher LC with BED more than 100 
Gy, again only 41 primary lung tumors were analyzed. Also, 
the small (37-patient) phase I dose escalation study in the 
Unites States pioneered by Timmerman et al.34 and establishing 
the RTOG standard of 20 Gy × 3 fractions (54 Gy or 18 Gy × 3 
 heterogeneity-corrected) for medically inoperable patients 
with peripherally located tumors used cast blocks with no 
IGRT beyond routine portal imaging.
Although our report represents the most modern and 
comprehensive retrospective analysis available, no random-
ized trials are available to compare NSCLC SBRT fraction-
ation schedules. The Cleveland Clinic 35 retrospectively 
analyzed and reported similar LC for lower BED (10 Gy × 
5 fractions; BED = 100 Gy) and higher BED (20 Gy × 3; 
BED = 180 Gy) in 94 NSCLC cases, however, follow-up was 
short with a significant follow-up time bias among treatment 
groups. All patients were treated using Novalis (BrainLab, 
Feldkirchen, Germany) allowing for only 2D set-up correction 
and verification. Also, the 60 Gy group was treated without 
heterogeneity correction, although retrospectively recalcu-
lated. The RTOG recently completed accrual to a randomized 
trial (RTOG 0915) but using an uncommon 34 Gy single-frac-
tion dose schedule (BED = 150 Gy), comparing it with 48 Gy 
in four fractions (BED = 106 Gy). The winner of that trial will 
then be compared with the 20 Gy × 3 schedule from RTOG 
0236, although using 54 Gy in three fractions for heterogeneity 
correction. Only 11 tumors in the current analysis of over 500 
were treated in a single fraction. The authors acknowledge that 
fewer patients were treated with dose schedules having a BED 
of less than 105 Gy in the current study than patients treated 
with higher doses. Although it would be difficult, on the basis 
of our data, to recommend a single particular dose schedule, 
the 48 Gy in regimen 4 is one arm of an RTOG trial for inoper-
able patients, the best reported and most commonly used mul-
tifraction schedule in Japan, and corresponds to a BED just 
over 105 Gy, the minimum dose for 3-year LC of more than 
90% in this study. It, therefore, might be considered the most 
appropriate minimum dose, outside of a trial, particularly if 
dose-limiting structures are a concern. For centrally located 
tumors, enrollment in RTOG 0813, the dose-finding study, is 
strongly encouraged, despite reports of schedules such as 50 
Gy in four fractions being well tolerated.36
Despite high LC rates using lung SBRT, further out-
come improvements can still be realized. Similar to other 
recent reports, the predominant recurrence pattern was DM.37 
Bradley et al.37 reported on 91 medically inoperable patients 
treated with 20 Gy × 3 (peripheral) or 9 Gy × 5 (central) where 
DM or second lung cancers were the most common recur-
rences and DM the major determinant of survival. Similarly, in 
RTOG 0236, a prospective trial of 59 patients treated with 60 
Gy in 3 fractions, 3-year DM was 22% and RR 13%,2 almost 
identical to the current report. Although 88% of our popula-
tion was PET-staged, lack of PET staging predicted for higher 
DM (27% without PET versus 19% PET). Time from stag-
ing PET to SBRT initiation was also an important outcome 
determinant, particularly of regional recurrence. However, RR 
was not impacted by either PET staging or more invasive stag-
ing like mediastinoscopy. Systemic therapy combined with 
SBRT has been only rarely studied6 and can be difficult in 
this fairly frail and elderly population. Chen et al.38 reported 
on 65 patients, (17 got adjuvant cisplatin-based chemotherapy 
1 week post-SBRT) and identified an OS and response ben-
efit with chemotherapy. However, most patients not receiv-
ing chemotherapy were medically unfit, introducing a highly 
probable survival selection bias. The subset of patients (3%) 
receiving chemotherapy in the current study was probably too 
small for a meaningful analysis. Hopefully newer and directed 
molecularly targeted agents will make future systemic treat-
ment more reasonable. Although conflicting data on adjuvant 
chemotherapy postsurgical resection for stage I NSCLC exist, 
investigation of chemotherapy in combination with SBRT will 
be increasingly important if SBRT has future applications in 
early-stage operable or more advanced stage NSCLC patients 
receiving chemoradiotherapy.39–43
SBRT’s seemingly overwhelming success in medi-
cally inoperable patients, plus reports of promising operable 
patient outcomes, led to several ongoing prospective stud-
ies comparing surgery with SBRT.44,45 In the current analy-
sis, 2-year OS was 78% in operable patients. The RTOG/
American College of Surgeons Oncology Group (ACOSOG) 
developed a randomized trial, RTOG 1021/ACOSOG Z4099, 
comparing limited resection +/– postoperative brachytherapy 
with SBRT for borderline operative candidates, activated in 
May 2011. Unfortunately, the Netherlands Trial of Either 
Surgery or Stereotactic Radiotherapy for Early Stage (IA) 
TABLE 5.  Cox Multivariate Regression Analysis of Factors 
Affecting Recurrence and Survival
Factors Predicting For Hazard Ratio p
Local recurrence
Prescription BED10 0.984 0.01
Elapsed days during SBRT 1.088 0.05
GTV maximum dimension (cm) 1.183 0.22
Regional recurrence
Time from PET to SBRT start (weeks) 1.050 0.08
Synchronous primary tumor 1.940 0.17
Distant metastasis
GTV maximum dimension (cm) 1.317 0.008
Squamous histology 1.741 0.07
Synchronous primary tumor 2.038 0.11
Overall survival
DLCO 0.909 0.005
Male sex 1.968 0.02
Time from PET to SBRT start (weeks) 1.080 0.02
GTV maximum dimension (cm) — 0.36
Cause-specific survival
GTV maximum dimension (cm) 1.372 0.03
Squamous histology 1.852 0.17
Age (years) — 0.39
BED
10
, biological equivalent doses; SBRT, stereotactic-body radiotherapy; PET, 
positron emission tomography; GTV, gross-tumor volume; DLCO, diffusing capacity 
for carbon monoxide.
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Lung Cancer (ROSEL) trial randomizing operative patients 
to surgery or SBRT closed because of lack of accrual. The 
William Beaumont Hospital retrospectively compared SBRT 
with wedge resection in 124 patients with T1–T2N0 NSCLC. 
SBRT was associated with lower LR (95% versus 76%), RR 
and locoregional recurrence, and equivalent CSS, but lower 
OS as a result of comorbidity imbalances among groups.6 A 
subsequent analysis including lobectomy patients, showed 
lobectomy as being overall superior to either SBRT or wedge 
resection.46 The Washington University recently compared 
462 surgical patients with 76 SBRT patients and reported a 
5-year OS of 55% surgery versus 32% SBRT. LC was superior 
with surgery for clinical stage IA for an unmatched cohort. 
In a propensity-matched comparison of 57 surgical and 57 
SBRT patients, no survival or LR differences were noted.7 
Future analyses of the current data set will detail operative 
and nonoperative outcomes but are beyond the scope of this 
report. While analyzing any retrospective, thought-provoking 
analysis of surgery (particularly lobectomy) in comparison 
with SBRT, one must remember: 1) the vast majority of all 
SBRT data to date are on medically inoperable patients with 
multiple comorbidities, 50% to 60% of whom die within 
3 years of radiation for noncancer reasons, limiting the poten-
tial to detect recurrences and metastases over time, and 2) LR 
after SBRT can be difficult to judge due to substantial SBRT-
induced changes in normal lung parenchyma, with FDG-PET 
not always helpful. We, like many in our field, are excited 
about the success of SBRT, which might have outcomes simi-
lar to limited surgery in terms of recurrence, with potentially 
lower morbidity and cost in selected patients, but still caution 
against using SBRT in operable patients outside of clinical tri-
als, such as the ongoing ACOSOG/RTOG trial.
CONCLUSIONS
In the largest stage I NSCLC the SBRT data set using 
3-D IGRT with evaluation of 3D and heterogeneous doses, the 
2-year lLC rate was 94% and heavily dependent on prescrip-
tion BED
10
 of 105 Gy or more. Pneumonitis of grade 2 or 
higher was uncommon (2%) with a myositis/rib fracture rate 
of 7% to 8%. DM (20%) was the predominant pattern of fail-
ure, and regional recurrences occurred in just more than 10% 
of patients. The 2-year OS was similar to that expected for a 
predominantly medically inoperable population at 58%; the 
survival in operable patients was encouraging at 78%.
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APPENDIX A.  SBRT Prescription Doses According to 
Institution
Institution
No. of 
Patients
BED
10 
(Gy)
Equivalent in
2-Gy Fractions 
(Gy)
William Beaumont Hospital 108
8.0 Gy × 5 = 40.0 Gy 1 72.0 60.0
6.0 Gy × 10 = 60.0 Gy 2 96.0 80.0
10.0 Gy × 5 = 50.0 Gy 1 100.0 83.3
12.0 Gy × 4 = 48.0 Gy 69 105.6 88.0
12.0 Gy × 5 = 60.0 Gy 34 132.0 110.0
20.0 Gy × 3 = 60.0 Gy 1 180.0 150.0
Netherlands Cancer Institute 187
15.0 Gy × 3 = 45.0 Gy 3 112.5 93.8
12.0 Gy × 5 = 60.0 Gy 2 132.0 110.0
18.0 Gy × 3 = 54.0 Gy 182 151.2 126.0
Thomas Jefferson University 21
4.2 Gy × 10 = 42.0 Gy 1 59.6 49.7
4.2 Gy × 12 = 50.4 Gy 2 71.6 59.6
8.0 Gy × 5 = 40.0 Gy 1 72.0 60.0
4.2 Gy × 15 = 63.0 Gy 1 89.5 74.6
10.0 Gy × 5 = 50.0 Gy 10 100.0 83.3
8.0 Gy × 8 = 64.0 Gy 1 115.2 96.0
12.0 Gy × 5 = 60.0 Gy 4 132.0 110.0
20.0 Gy × 3 = 60.0 Gy 1 180.0 150.0
Princess Margaret Hospital 129
18.0 Gy × 1 = 20.0 Gy 1 50.4 42.0
5.0 Gy × 9 = 45.0 Gy 1 67.5 56.3
5.0 Gy × 10 = 50.0 Gy 7 75.0 62.5
24.0 Gy × 1 = 24.0 Gy 1 81.6 68.0
7.5 Gy × 8 = 60.0 Gy 13 105.0 87.5
12.0 Gy × 4 = 48.0 Gy 59 105.6 88.0
18.0 Gy × 3 = 54.0 Gy 27 151.2 126.0
20.0 Gy × 3 = 60.0 Gy 20 180.0 150.0
University of Wuerzburg 60
7.0 Gy × 5 = 35.0 Gy 1 59.5 49.6
10.0 Gy × 3 = 30.0 Gy 6 60.0 50.0
8.0 Gy × 5 = 40.0 Gy 1 72.0 60.0
6.0 Gy × 8 = 48.0 Gy 7 76.8 64.0
12.5 Gy × 3 = 37.5 Gy 35 84.4 70.3
8.0 Gy × 6 = 48.0 Gy 1 86.4 72.0
26.0 Gy × 1 = 26.0 Gy 9 93.6 78.0
All cases 505 — —
BED
10
, biological equivalent doses; SBRT, stereotactic-body radiotherapy.
